title: DVT Management and Outcome Trends, 2001 to 2014.
abstract: BACKGROUND
  A comprehensive evaluation of temporal trends in the treatment of patients who have DVT may assist with identification of modifiable factors that contribute to short-term outcomes.
  
  
  METHODS
  We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies among 26,695 adults with DVT enrolled in the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2014. We also examined temporal trends in risk-adjusted rates of all-cause, pulmonary embolism-related, and bleeding-related death to 30 days after diagnosis.
  
  
  RESULTS
  The mean length of hospital stay decreased from 9.0 days in 2001 to 2005 to 7.6 days in 2010 to 2014 (P < .01). For initial DVT treatment, the use of low-molecular-weight heparin decreased from 98% to 90% (P < .01). Direct oral anticoagulants use increased from 0.5% in 2010 to 13.4% in 2014 (P < .001). Risk-adjusted rates of 30-day all-cause mortality decreased from 3.9% in 2001 to 2005 to 2.7% in 2010 to 2014 (adjusted rate ratio per year, 0.84; 95% CI, 0.74-0.96; P < .01). VTE-related mortality showed a nonstatistically significant downward trend (adjusted rate ratio per year, 0.70; 95% CI, 0.44-1.10; P = .13), whereas 30-day bleeding-related mortality significantly decreased from 0.5% in 2001 to 2005 to 0.1% in 2010-2014 (adjusted rate ratio per year, 0.55; 95% CI, 0.40-0.77; P < .01).
  
  
  CONCLUSIONS
  This international registry-based temporal analysis identified reductions in length of stay for adults hospitalized for DVT. The study also found a decreasing trend in adjusted rates of all-cause and bleeding-related mortality.
authors.affiliation: Respiratory Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
authors.forename: Raquel
authors.initials: R
authors.lastname: Morillo
authors.affiliation: Respiratory Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Electronic address: djimenez.hrc@gmail.com.
authors.forename: David
authors.initials: D
authors.lastname: Jiménez
authors.affiliation: Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Aibar
authors.affiliation: UOSD Angiologia e Diagnostica Vascolare, Ospedale SS, Filippo e Nicola, Avezzano, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Mastroiacovo
authors.affiliation: Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ontario, Canada.
authors.forename: Philip S
authors.initials: PS
authors.lastname: Wells
authors.affiliation: Department of Internal Medicine, Hospital Reina Sofía, Navarra, Spain.
authors.forename: Ángel
authors.initials: Á
authors.lastname: Sampériz
authors.affiliation: Department of Internal Medicine, Centro Hospitalar Gaia/Espinho, Entidade Pública Empresarial, Vila Nova de Gaia, Portugal.
authors.forename: Marta
authors.initials: M
authors.lastname: Saraiva de Sousa
authors.affiliation: Biostatistics Department, Ramón y Cajal Hospital and IRYCIS, Centro de Investigación Biomédica En Red, Epidemiología y Salud Pública, Madrid, Spain.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Muriel
authors.affiliation: Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri.
authors.forename: Roger D
authors.initials: RD
authors.lastname: Yusen
authors.affiliation: Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona; Universidad Católica de Murcia, Murcia, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Monreal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D002423:Cause of Death; D015331:Cohort Studies; D019468:Disease Management; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007902:Length of Stay / Q000639:trends*; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D011158:Population Growth; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data / Q000639:trends*; D016306:Vena Cava Filters / Q000706:statistics & numerical data / Q000639:trends*; D020246:Venous Thrombosis / Q000401:mortality / Q000628:therapy*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight
keywords: DVT; prognosis; survival